“Purpose of reviewThe incidence of obesity and its associated comorbidities have significantly increased over the years with adverse health and financial consequences for society. Lifestyle changes are
OSI-744 concentration essential for the prevention and treatment of obesity but their benefit appears limited as inadequate and nonsustained weight loss results have been reported. Pharmacotherapy is frequently advocated as part of a weight loss strategy. In this review, we will discuss the antiobesity drugs with Food and Drug Administration approval and their cardiovascular implications.Recent findingsOrlistat (Xenical) remains the single monotherapy that has approval in Europe. Topiramate (Topamax) and phentermine have long been approved in the United States, whereas lorcaserin and the extended release combination of phentermine with topiramate have recently gained approval. The development of single peptides targeting gut hormones or other host signals related to obesity may represent promising therapeutic options.SummaryDespite the recent failures of a number of antiobesity drugs, the pharmacotherapy of obesity is progressing rapidly. Treating the
YM155 solubility dmso obese cardiovascular patient has proven challenging. Efficacy, safety and the sustainability of weight loss are key areas of focus in drug development strategies.”
“Six naturally occurring terpenoids were isolated from the hexane extract of rabbit-head wormwood Artemisia lagocephala (Fisch. ex Besser) DC. The terpenoids’ structures were elucidated by spectroscopic and chemical methods as 3 beta-acetoxycycloartan-24-ozonide (1), 3 beta-acetoxycycloartan-24-al (2), 25,26,27-trisnor-3 beta-acetoxycycloartan-24-ol (3), 24,25,26,27-tetranor-3
beta-acetoxycycloartan-23-ol (4), and the previously known caryophyllene oxide (5) and (1R,4S)-p-menth-2-en-1-ol (6). (C) 2011 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.”
“Purpose of review
Stem cell transplantation is currently generating a great deal of interest in the treatment of ischemic heart disease (IHD) as the replacement selleck chemical of akinetic scar tissue by viable myocardium should improve cardiac function, impede progressive left ventricular remodeling, and revascularize ischemic areas. Substantial work in stem cell therapy for ischemic heart disease has recently been reported.
Stem cell populations have been expanding. Most recently, induced pluripotent stem (iPS) cells have been discovered that have the potential to revolutionize stem cell therapy. Many of the efforts in stem cell therapy for ischemic heart disease have been inconclusive and often contradicting. Transdifferentiation of stem cells into cardiomyocytes remains controversial. The therapeutic effect of the stem cell seems consistent with paracrine function rather than transdifferentiation, Systemic and micromilieu factors appear to dictate the fate of implanted stem cells.